SELLAS Life Sciences Group (SELLAS) has announced promising results of
a Phase 1 clinical trial of the combination of immunotherapy agents
Galinpepimut-S (GPS) and nivolumab for patients with WT1 positive malignant pleural mesothelioma.
GPS is an immunotherapeutic which targets the Wilms Tumor 1 (WT1) protein
which is present and over-expressed in an array of hematological malignancies
and solid tumors.
The trial included eight patients with stage III and IV mesothelioma who
experienced disease recurrence after undergoing the standard frontline
treatment of chemotherapy with pemetrexed. All eight patients were administered
three or more doses of GPS and experienced median overall survival of
9.4 months, and 10.5 months for patients who received the combination
therapy of GPS with nivolumab. Overall disease-free progression ranged
from 11.1 weeks to 11.9 weeks.
GPS is also being researched as an immunotherapy agent in the treatment
cancers that express WT1, one of the most widely expressed cancer antigens,
including leukemia, breast cancer, and ovarian cancers.
Click here for more.